Exelixis Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
All right. Welcome, everyone. This is Joshua Schimmer from the Evercore ISI biotech team. (inaudible) President and Chief Executive Officer of Exelixis, we have Mike Morrissey. Good to see you. Welcome back to our health care conference. I'm thinking cabo is still is the primary value driver for Exelixis in the near term. So maybe we can talk about some of the trials that could drive that near-term inflection. What might be left after cabo for 092 and then hopefully have some time to talk about the evolving pipeline.
Questions & Answers
So as we think about the major growth drivers for cabo, both within renal and then also additional indications, what should we be looking for? And like what are your highest hopes?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
